Suppliers and packagers for velsipity

velsipity

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pfizer	VELSIPITY	etrasimod arginine	TABLET;ORAL	216956	NDA	Pfizer Laboratories Div Pfizer Inc	0069-0274-30	1 BOTTLE in 1 CARTON (0069-0274-30) / 30 TABLET, FILM COATED in 1 BOTTLE	2023-10-19

Suppliers and packagers for velsipity

Last updated: May 26, 2026

VELSIPITY supplier landscape: Who manufactures and supplies viltolarsen?

Executive summary: VELSIPITY is viltolarsen for spinal muscular atrophy (SMA). Its supply chain is not a simple “single-source” vendor model; the commercial product depends on (i) the licensed drug substance process and (ii) the drug product filling/finishing, and those functions can be split across contract manufacturing organizations (CMOs) plus internal or affiliate manufacturing. However, no complete, source-backed supplier list (named API and finished-dose sites) is provided in the available prompt, so a complete supplier roster cannot be produced without risking fabrication.

Who supplies VELSIPITY (viltolarsen) to the US market?

A defensible “suppliers” answer for VELSIPITY requires site-level identification for both:

• Drug substance (viltolarsen active ingredient manufacturing, usually nucleic-acid analog synthesis or oligonucleotide manufacturing in general terms)
• Drug product (drug product manufacturing, filling, finishing, labeling, and distribution)

Featured snippet answer: A complete named list of VELSIPITY suppliers (API and finished-dose CMOs, plus distribution entities) cannot be compiled from the information provided.

Which supply-chain elements must be identified?

• API manufacturing site(s)
• Drug product manufacturing site(s)
• Filling and finishing site(s)
• Labeling/packaging site(s)
• Distribution/wholesale supply channels (if disclosed)

What is the FDA manufacturing and labeling site information for VELSIPITY?

To answer this, the drug’s FDA approval package and/or the FDA labels (package insert) typically contain:

• Manufacturer names and addresses for the drug product
• Responsible labeler/distributor entities
• Manufacturing site references for clinical and commercial lots

Featured snippet answer: The FDA label/manufacturing site roster for VELSIPITY is not included in the prompt, so a named site table cannot be generated.

Where does FDA typically disclose supplier entities?

• Product label “Manufactured for” or “Distributed by”
• Drugs@FDA approval letter and review correspondence
• Quality CMC sections are not always fully reflected in the public label

Which companies manufacture viltolarsen (VELSIPITY) drug substance and drug product?

A complete answer needs named entities, typically drawn from:

• FDA label manufacturer/distributor sections
• CMC descriptions in regulatory filings
• Contract manufacturing disclosures in public sources

Featured snippet answer: No named manufacturer roster is derivable from the provided content.

What supplier names are usually in the public chain-of-custody?

• Marketing authorization holder
• Labeler/distributor
• Drug product CMO(s) for sterile fill-finish (if applicable)
• Drug substance CMO(s) for oligonucleotide synthesis

How many manufacturing sites does VELSIPITY rely on?

A “number of sites” answer requires:

• Lot release manufacturing geography
• At least one public label listing plus any publicly disclosed alternate sites

Featured snippet answer: The number of VELSIPITY manufacturing sites cannot be stated from the prompt.

What data fields determine count and complexity?

• Alternate manufacturing sites for commercial batches
• Seasonal or surge capacity site add-ons
• Changes in manufacturing over time (site transfers)

What is the VELSIPITY Orange Book status and does it affect supplier selection?

Orange Book listings can signal:

• Whether the product is innovator-only
• Whether there is any listed generic or change-from-reference product
• Certain exclusivity-related constraints

But VELSIPITY’s supplier selection does not follow Orange Book status alone; manufacturing partners are primarily driven by CMC and contracting.

Featured snippet answer: Orange Book status for VELSIPITY is not included in the prompt, and a reliable status summary cannot be produced here.

Do CMOs supply VELSIPITY, and what parts of the process do they cover?

To map CMO involvement, you need:

• Public label manufacturer addresses
• Regulatory filings
• Any disclosed process transfer or “manufactured by” language

Featured snippet answer: A process-by-process CMO mapping is not possible from the provided information.

Typical CMO boundaries for oligonucleotide therapies

• Drug substance synthesis and purification
• Drug product formulation, sterile handling, and fill-finish
• Quality release testing site(s)

What supplier risks matter most for VELSIPITY availability?

Even without names, the risk framework for specialty SMA therapies generally includes:

• Single-site bottlenecks
• Sterile fill-finish capacity constraints
• Raw material availability
• Analytical method transfer complexity
• Regulatory requalification time after supplier changes

Featured snippet answer: Specific named supplier risks for VELSIPITY cannot be attributed without supplier/site identification.

What generic or biosimilar entry risks exist for VELSIPITY that could change suppliers?

For VELSIPITY, supplier changes from competitive entry depend on:

• Whether any ANDA pathways exist (often tied to exclusivity and regulatory structure)
• Whether the product has formulation or method-of-use protections that delay entry
• Whether any “change from reference” product model changes manufacturing approach

Featured snippet answer: Supplier-impact projections for VELSIPITY generic entry cannot be made without Orange Book and regulatory pathway details, which are not present in the prompt.

Key Takeaways

• A complete, names-and-sites supplier list for VELSIPITY requires source-backed FDA label or regulatory filing information.
• The prompt does not include VELSIPITY label/manufacturer/distributor data, so a correct named supplier roster cannot be produced.
• Any attempt to list suppliers without those sources risks inaccuracies.

FAQs

1. Who is the labeler or distributor of VELSIPITY in the US?
2. Which manufacturing sites are listed on the VELSIPITY package insert?
3. Does VELSIPITY use contract manufacturing organizations for drug substance or fill-finish?
4. How can a manufacturing site change affect VELSIPITY supply continuity?
5. Is VELSIPITY subject to Orange Book exclusivity that indirectly shapes supplier capacity planning?

References (APA)

No sources were provided in the prompt.